Enlarged prostate Benign, also referred to as benign prostatic hyperplasia (BPH), is a common occurrence in aging men. During the past decade, the role of primary care physicians (PCPs) in managing enlarged prostate (EP) has increased considerably.
Enlarged prostate becomes more common as men age, occurring in more than half of those aged between 50 and 60 years. Other risk factors that have been reported for enlarged prostate include nationality and marital status. Clinical manifestations of Enlarged prostate range from various degrees of lower urinary tract symptoms (LUTS) to AUR and renal failure. Clinically, patients are usually identified by the presence of LUTS, by prostate enlargement found on digital rectal examination (DRE), or by elevated prostate-specific antigen (PSA) measurement during a routine examination.
Statistics for the United States
Prevalence (2000) for Enlarged prostate is 6.5 million of the 27 million Caucasian men aged 50 to 79 in the United States were expected to meet the criteria for discussing treatment options for BPH.
Enlarged prostate with diagnosis BPH/LUTS (AUA Symptom Score of 7 or greater) prevalence estimates for different ages: 40–49: 24 percent, 50–59 : 31 percent, 60–79: 36 percent and 70–up: 44 percent

Costs in 2000 Enlarged prostate (BPH/LUTS) it's $1.1 billion annually in direct expenditures for medical services provided at hospital inpatient and outpatient settings, emergency departments, and physicians’ offices.
  1. Infection (Women & Men) = $3.5 Billion
  2. Kidney Stones = $2.1 Billion
  3. Prostate Cancer = $1.3 Billion
  4. Bladder Cancer = $1.1 Billion
  5. BPH/Prostate Enlargement = $1.1 Billion
  6. Urinary Incontinence = $463.1 Million
  7. Kidney Cancer = $401.4 Million
  8. Erectile Dysfunction = $327.6 Million
  9. Prostatitis = $84.4 Million
  10. Interstitial Cystitis/PBS = $65.9 Million